What is RNA and how can we use the body's own RNA editing machinery to treat disease? Learn more about the Axiomer® RNA editing technology and how we are creating a new class of medicines.
… Axiomer technology - RNA base editing ProQR invented an … a new way to use RNA oligonucleotides to alter RNA. The Axiomer™ RNA editing technology enables the editing of … partnership Lilly partnership The first partner for the Axiomer™ technology is Eli Lilly and Company. The global …
ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly.
ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
… Investor/Analyst Webcast: Lilly Partnership Expansion and Axiomer Overview ProQR Management will host an investor … conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the … 30 days following the presentation date. About Axiomer ® ProQR is pioneering a next-generation RNA base …
Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.
On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.